(Fighting against new crown pneumonia) How much is it? Who can fight? Focus on China's first conditionally listed new crown vaccine
China News Service, Beijing, December 31st, title: How much is it?
Who can fight?
Focus on China's first conditionally listed new crown vaccine
Author Li Jingze
On the 31st, Chinese officials announced at the press conference of the Joint Prevention and Control Mechanism of the State Council of China that the Sinopharm China Bio-New Crown Inactivated Vaccine has been approved by the State Drug Administration for conditional listing.
What is the price of this China's first conditionally listed new crown vaccine?
Who can inject?
At the press conference, the heads of relevant departments such as the China National Medical Products Administration and the National Health Commission answered one by one.
how much is it? free
Regarding the pricing of the new crown vaccine, Zeng Yixin, deputy director of the National Health Commission of China and head of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, said that the basic attribute of the vaccine is a public product, and the price may vary according to the scale of use. Variety.
"But a major premise is that it must be provided for free for all."
Accessibility? All the people "should take it all"
Zeng Yixin revealed that in the next step, with the approval of the vaccine’s conditional listing, China will comprehensively and orderly promote the vaccination of the elderly and high-risk groups with underlying diseases, and follow up with other general population vaccination.
He said that at present, the Chinese Expert Advisory Committee for Immunization Program has formulated a unified vaccination plan, and vaccination will be carried out in an orderly manner. All eligible people will be able to achieve "every need" and gradually build an immune barrier for the entire population to block the new coronavirus. Spread, so that the new crown pneumonia epidemic can be completely controlled.
safety? good
The safety of the vaccine generally refers to whether the subject will have adverse reactions after vaccination, and the severity of the adverse reactions.
Zeng Yixin said at the meeting that China launched COVID-19 vaccination for high-risk groups and key groups in June and December this year. The two injections totaling 4.5 million doses fully proved the safety of China’s vaccines.
"Of course, a certain proportion of adverse reactions occurred. The total incidence is very close to those of the inactivated vaccines routinely vaccinated. The main manifestations are some local pain and local induration." Zeng Yixin said that the number of mild fever cases is probably less than 0.1 %, the incidence of more serious adverse reactions such as allergic reactions is about two per million. "These conditions have been treated in time and have been well treated."
Effectiveness? Protection rate 79.34%
The effectiveness of a vaccine usually refers to whether the recipient will be infected when exposed to a pathogen after being vaccinated, or the degree of infection.
Previously, existing data showed that the protection rate of the first conditionally listed new crown vaccine in China was 79.34%, achieving the unity of safety, effectiveness, accessibility, and affordability, and meeting the requirements of the relevant standards of the World Health Organization and the State Food and Drug Administration .
Regarding whether the mutation of the new coronavirus will affect the effectiveness of the vaccine, Xu Nanping, Vice Minister of Science and Technology of China, pointed out that there is currently no evidence that the mutation we have observed will have a substantial impact on the effectiveness of the vaccine, but China will produce it according to certain circumstances. Influence to carry out scientific and technological work deployment.
Capacity? Can meet the domestic demand for large-scale vaccination
Regarding China’s new crown virus vaccine production capacity, Mao Junfeng, head of the Consumer Goods Industry Department of the Ministry of Industry and Information Technology of China, said that with the further increase in the production capacity of the new crown inactivated vaccine and the gradual completion of other technical routes and enterprise production routes, China’s new crown virus vaccine The production capacity can meet the domestic demand for large-scale vaccination.
According to Mao Junfeng, according to the dispatch situation, there are currently 18 domestic companies that have successively carried out capacity building in accordance with the development of their respective new coronavirus vaccines.
He pointed out that vaccine production capacity is actually a process of dynamic and continuous improvement. “While these companies are carrying out large-scale production, we are also organizing them to expand their production capacity simultaneously.”
Supervision? Full traceability management
Regarding the post-marketing supervision of vaccines with additional conditions, Chen Shifei, deputy director of the China National Medical Products Administration, said that the drug regulatory and inspection agencies of Beijing and Hubei have been granted to undertake the batch issuance of new coronavirus vaccines.
After the new coronavirus vaccine is on the market, the batch issuing agency will implement strict data review and laboratory testing on each batch of vaccines in accordance with relevant regulations and biological product batch issuing methods to ensure that each vaccine is qualified.
He said that we have strengthened the entire chain of vaccine supervision.
The State Food and Drug Administration, in conjunction with the National Health Commission, has established a vaccine information traceability system, and has basically realized the traceability management of the entire vaccine market.
(Finish)